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CUNICAL INVESTIGATION
Circulating luteinizing hormone receptor inhibitor(s) in boys with
chronic renal failure
LEO DUNKEL, TANELI RAIvIo, JARMO LAINE, and CHRISTER HOLMBERG
Children s Hospital, University of Helsinki, SF-00290 Helsinki, Finland
Circulating luteinizing hormone receptor inhibitor(s) in boys with
chronic renal failure. Patients with chronic renal failure frequently have
hypogonadism. To elucidate the molecular mechanisms involved, we
tested the ability of serum from these patients to inhibit recombinant
human luteinizing hormone receptors. Using a cell line expressing func-
tional human luteinizing hormone receptors, we found that adenosine
3',5'-monophosphate (cAMP) production was markedly inhibited by sera
from the patients, but not by sera from healthy subjects. Inhibition of
cAMP production was associated with inhibition of '251-human chorionic
gonadotropin binding. Inhibition of LH receptors by sera from patients
correlated with the glomerular filtration rate and after renal allograft
transplantation, decreased. Fractionation of serum samples indicated the
receptor-inhibiting activity in proteins of molecular weights from 30,000 to
60,000 Daltons. When characterized and purified, the factor responsible
may well be a new LH receptor antagonist of clinical significance.
In chronic renal failure (CRF), various endocrine axes, includ-
ing the hypothalamo-pituitary-testicular axis, are susceptible to
significant pathophysiological alterations [1, 21. In uremic boys,
bone age is delayed and pubertal maturation is often impaired or
arrested, and in uremic men, clinical hypogonadism, consisting of
diminished libido and potency and impaired fertility, may develop
despite otherwise effective peritoneal dialysis or hemodialysis.
Alterations at both the pituitary and gonadal levels have been
implicated in the pathophysiology of this condition in animal
[3—81, and human [9—111 studies. Recent investigations evaluating
pulsatile luteinizing hormone (LH) secretion have shown a re-
duced frequency of plasma LH pulses, implying the existence of a
hypothalamic abnormality in uremia [6, 8, 11]. Functional impair-
ment of the pituitary-gonadal axis may also be due to deficient
Leydig cell steroidogenic function, since in uremic rodents [3, 5]
and in men [9, 12] the testicular response to LH/hCG tends to be
reduced, and reduced circulating LH bioactivity has been re-
ported in chronic renal failure [91.
This observed impairment of steroidogenic capacity prompted
us to study whether the serum of patients with CRF contains a
factor capable of interacting with recombinant human LH recep-
tors in vitro, which would explain the hypogonadism. Using a
human cell line expressing functional LH receptors, we found that
patients with CRF have circulating receptor inhibitors capable of
interacting with recombinant human LH receptors by inhibiting
adenosine 3',S'-monophosphate (cAMP) production. This novel
receptor inhibitor could explain the impaired Leydig cell andro-
gen biosynthesis and hypogonadism seen in chronic renal failure.
This finding raises the possibility of characterizing a naturally
occurring substance with unique LH receptor-blocking ability.
Methods
Nine boys with chronic renal failure due to various causes were
studied (Table 1). The patients were studied at three different
stages of their disease: in the first examination, they were having
conservative treatment for CRF (7 patients, 9 samples); in the
next stage they had developed end-stage renal disease, which was
treated with continuous ambulatory peritoneal dialysis (CAPD; 8
patients, 9 samples); and the last examination took place after the
patients had received a renal allograft (8 patients, 8 samples). The
diseases leading to end-stage renal disease were nephronophthisis
and reflux nephropathy due to congenital urethral valve, both in
three patients, and congenital nephrotic syndrome, polycystic
kidney disease and post-streptococcal glomerulonephritis, all in
one patient each. Post-renal transplantation blood samples were
drawn a mean time of nine months after transplantation (range I
to 18 months). Seven of the nine patients received antihyperten-
sive medication at the of blood sampling (all sampling times
included). All except two of these patients received the same type
of drug (calcium channel blocker or a-receptor blocker) both
before and after transplantation. The two patients received a
calcium channel blocker only after transplantation. Fifteen age-
matched prepubertal boys, with no evident endocrine abnormal-
ity, were studied as controls (Table 1). The study was approved by
the Ethics Committee of the Children's Hospital, University of
Helsinki, Finland.
Reagents and hormones
Purified hCG (CR-127; 14,900 lU/mg) was obtained from the
National Hormone and Pituitary Distribution Program, NIDDK,
NIH. Purified human LH (WHO IRP 68/40) and 3-methyl
isobutyixanthine were purchased from Sigma Co. (St. Louis, MO,
USA). Cyclic AMP antibodies and '25l-cAMP were purchased
from ICN Immunobiologicals (Costa Mesa, CA, USA).
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Gonadotropin immunoassays
Plasma LH and FSH levels were measured by time-resolved
immunofluorometric assays (IFMAs), using reagents from Waliac
(Kabi Pharmacia, Turku, Finland) as previously described [14].
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Table 1. Clinical data of the patients with chronic renal failure
according to the stage of the disease
On continuous
ambulatory After renal
On conservative peritoneal allograft
treatment dialysis transplantation Controls
Number of 7 8 8 15
patients
Age years 7.4 1.3 7.2 1.2 8.9 3.0 7.7 1.9
Pubertal G1P1 G1P1 G1P1 G1P1
stage°
Serum LH 0.8 0.6 0.9 0.7 0.5 0.3 0.4 0.4
lU/liter
Serum FSH 1.0 0.4 1.0 0.4 1.1 0.4 0.9 0.5
lU/liter
Glomerular 15.0 3.4 9.3 0.7 72.9 4.8
filtration
rateb ml!
min/1.73
m2
Values are means SE.
According to Tanner [13]
b According to Schwartz et at [27]
The LH standards were calibrated against WHO IRP 68/40, and
FSH standards against the second IRP of pituitary FSH/LH
(78/549). The assay sensitivity was 0.019 lU/liter for LH and 0.014
lU/liter for FSH as defined by the mean 2 SD of 12 replicates of
a zero sample. Intra-assay coefficients of variation (CVs) were
2.5% and 2.1% (midrange), and interassay CVs were 4.5% and
4.1% for LH and FSH, respectively.
Expression of recombinant human LH receptors
The cDNAs coding for the entire human LH receptors were
inserted into the pCMX expression vectors [15]. A human fetal
kidney cell line (293) was used for the expression of the receptors.
The cells were transiently transfected with the expression plas-
mids, using the calcium phosphate precipitation method [161.
Human LH receptor-based bioassays
For determination of cAMP production, LH receptor-express-
ing cells (2 x 105/tube) were treated with varying concentrations
of purified hCG and LH (WHO IRP 68/40) as standards or with
duplicate serum samples at three dose levels (3, 10, and 30 gil).
The cells were then cultured for 18 hours in Dulbecco's minimal
essential medium (DME; Gibco, Santa Clara, CA, USA) contain-
ing 5% calf serum in the presence of 0.25 m 3-methyl isobutyl-
xanthinc. At the end of culture, extracellular cAMP levels were
determined by specific RIA [17]. Intra-assay and inter-assay CVs
of the cAMP RIA were 4.5% and 9.3% (midrange), respectively.
The assay sensitivities was 3.0 lU/liter, as defined by mean 2 SD
values of cAMP production by 12 replicate of non-treated cultures
for the human LH receptor-based LH bioassay. LH and hCG
standards showed parallel dose-dependent stimulation of cAMP
production in the assays (data not shown).
Radioligand receptor assay
lodination of hCG (CR-127) was performed using the lactoper-
oxidase method, as previously described [18]. The '25l-hCG tracer
was characterized by measuring its specific activity (100,000
cpm/ng) and maximal binding (45%) in a radioligand receptor
assay using rat testicular membranes [191. Non-specific binding
was determined by adding a 1000-fold excess of unlabeled ligand
(Pregnyl; Organon, Oss, The Netherlands). LH receptor binding
in transfected 293 cells was performed by incubating the cells (2 x
105/tube) with sera for two hours at 22°C, after which '251-hCG
was added. After incubation for another 18 hours, the samples
were diluted fivefold with ice-cold Dulbecco's PBS (2 ml; DPBS)
supplemented with 0.1% BSA and centrifuged at 800 >( g for 15
minutes at 4°C. The pellets were washed twice with DPBS and,
after the supernatant was discarded, were measured for radioac-
tivity with a gamma counter.
Preliminary characterization of the inhibitor
For estimation of the molecular size of the inhibitor, sera from
five subjects with CRF, showing high levels of LH receptor
inhibiting activity, were fractionated using Centricon microcon-
centrators (Amicon, Danvers, MA, USA), with sizing limit at
molecular weights of 10,000, 30,000, 60,000 and 100,000. After
each fractionation step, serum was recovered into the initial
volume by adding culture medium. Each of the serum fractions
thus obtained was used to test the activity of LH receptor inhibitor
in human LH receptor-based bioassay by measuring cAMP pro-
duction. The protein nature of the stimulator was also tested by
incubating sera from five subjects with CRF, showing high LH
receptor inhibiting activity, with 5 j.tg/ml of trypsin (Sigma) at
37°C for 18 hours, followed by addition of 50 jrg/ml of soyabean
trypsin inhibitor. Since we had found that the inhibitor has
molecular size larger than 30,000 Daltons, we separated trypsin
(24,000 Daltons) from the putative inhibitor (30,000 to 60,000
Daltons) using Centricon microconcentrators with a molecular
weight size limit of 30,000 Daltons before the assay.
Immunocytochemistiy
Since the lower binding of radiolabeled hCG to human LH
receptor expressing cells preincubated with sera from patients
with chronic renal failure could have resulted from decreased
receptor expression, the following immunocytochemical method
was used to study receptor expression. An antibody was raised in
rabbits to a synthetic peptide corresponding to amino acid resi-
dues 194-207 within the predicted extracellular domain of the
human LH receptor. For immunocytochemistiy, the antibody was
specified as follows. There was minimal or no staining with
replacement of the first antibody with equivalent dilutions of
preimmune IgG or by preabsorption of the first (specific) antibody
with the peptide against which it was raised. Furthermore, on
Western analysis of membrane proteins from 293 cells transfected
with the human LH receptor eDNA, a band with a mol wt
compatible with that of the glycosylated human LH receptor
protein was stained with the antibody. This band was abolished
when the first antibody was replaced with preimmune serum or
pcptide preabsorbed first antibody, providing additional evidence
for the specificity of the antibodies.
All the incubations were performed at 37°C in a humid chamber
on 293 cells (transfected and non-transfected) affixed to glass
slides. After blocking of the nonspecific biding sites with fulL
porcine serum for 30 minutes at RT, the slides were incubated
with sera obtained from control subjects or patients with chronic
renal failure for three hours, followed by three washes with PBS
(10 mm each). After this the slides were incubated with a
polyclonal antiserum to an extracellular portion the human LH
Serum I FSK Serum jil
2pM
Fig. 1. Inhibitory effect of serum taken from five representative patients in end-stage renal failure on cAMP accumulation in 293 cells expressing human LI-I
receptors. Extracellular cAMP accumulation was measured after incubation of the transfected cells (A) in the presence of hCG standard, (B) in the
presence of a near-saturating concentration (10 ng/ml) of hCG, and in the absence or presence of three different amounts of serum taken from patients
with chronic renal failure (0) or from control subjects (0), (C) in the presence of 2 mu of forskolin (FSK) and in the absence or presence of three
different amounts of serum taken from patients with chronic renal failure (0). Data are means of 4 cultures.
receptor diluted 1:100. The slides were washed three times (10
mm each) with PBS, followed by incubation for 1.5 hours with
FITC-conjugated goat immunoglobulins to rabbit immunoglobu-
lins (containing 5% porcine serum in PBS). After washing, the
slides were viewed in fluorescence microscopy.
Statistical analysis
Results are presented as the mean SE of three to four
replicate determinations. The analysis of variance (ANOVA)
followed by Scheffe's F-test or Student's t-test was used, when
appropriate, to determine significance of differences between
mean values [20]. For all statistical analysis between different
groups of patients, only one sample per patient was used. For
Lineweaver-Burk plot analysis, bound and free hormone concen-
trations were calculated and their inverse values analyzed by
linear regression analysis [21].
Results
Plasma levels of immunoreactive LH
Immunoreactive LH levels in serum samples from boys with
chronic renal failure were similar to levels in normal boys at all
stages of their disease (Table 1).
Serum LH receptor inhibitor(s) in boys with chronic renal failure
In the bioassay based on cAMP production by cells expressing
human LH receptors, sera from the boys with chronic renal failure
showed substantial inhibitory activity preventing cAMP accumu-
lation (Fig. 1B). In contrast, all normal boys had undetectable LH
receptor-inhibiting activity (Fig. 1B). To insure that the observed
failure of cAMP to accumulate was indeed due to inhibition of the
LH receptors on cAMP production, the effect of patient sera was
also studied after stimulating cells expressing LH receptors with
forskolin, a direct adenylyl cyclase activator. In these cells, cAMP
production was not inhibited by the sera of the patients (Fig. 1C).
This finding confirmed that the inhibition of cAMP production by
sera of boys with chronic renal failure was mediated by human LFI
receptors.
The inhibition of cAMP production in cells expressing LII
receptors by the sera of the patients was strongly dependent on
the stage of the disease. Inhibition of cAMP production was
strongest when patients were either receiving conservative treat-
ment or being treated with peritoneal dialysis (Fig. 2A). After the
patient had received a renal allograft, the level of inhibition was
relatively low, indicating that the inhibitory effect of the patient's
serum is at least partly a reversible phenomenon. Furthermore,
the inhibition of cAMP production correlated inversely with the
glomerular filtration rate (Fig. 2B).
Inhibition of '251-hCG binding in cells expressing human LH
receptors by patient sera
Preincubation of cells expressing human LH receptors with sera
from boys with chronic renal failure inhibited the binding of
radiolabeled hCG in a dose-dependent manner (Fig. 3). At the
highest dose of serum (30 /Ll), the '251-hCG binding was only 16
2% of the maximal binding when the cells were coincubated with
sera from patients treated with peritoneal dialysis, 23 4% with
sera from patients treated conservatively. After renal allograft
transplantation, inhibition of hCG binding was less strong; it was
79 5% of the maximal binding when the cells were eoincubated
with sera from patients of this group (Fig. 3). In contrast, none of
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the serum samples from healthy children inhibited binding of
radiolabeled hCG. The difference in inhibition of 1251-hCG bind-
ing between the healthy boys and the boys with chronic renal
failure was significant (P < 0.01—0.001; Fig. 3B). The inhibition of
the ligand binding to LH receptors by the patient serum corre-
lated inversely with the glomerular filtration rate (Fig, 3C).
Since the putative LH receptor inhibitor appeared to interact
with the ligand-hinding domain of the receptor, we performed a
saturation analysis to further clarify inhibitor-receptor interac-
tions. After incubation with increasing concentrations of labeled
hCG, a dose-dependent increase of specifically bound 1251-hCG
was detected in cells expressing human LH receptors, whereas no
specific binding was observed in nontransfected cells (data not
shown). Coincubation with varying amounts of patient sera inhib-
ited '251-hCG binding in a dose-dependent manner (Fig. 4). Sera
taken from patients with chronic renal failure appeared to reduce
the total number of available binding sites. Kinetic analysis using
Lineweaver-Burk plots showed that coincubation of patient sera
and 1251-hCG decreased maximal binding of '251-hCG (P < 0.005)
without significantly affecting the apparent Kd value (Table 2, Fig.
4GB). These results indicate that the inhibition of 2s1hCG
binding by patient sera was non-competitive.
Molecular size and proteineous nature of the LH receptor inhibitor
in sera of patients with CRF
To estimate of the molecular size of the serum factor inhibiting
human LH receptors in patients with CRF, sera from five patients
were separated using microconcentrators into fractions consisting
of molecular weights ranging from less than 10,000 to above
100,000 Daltons. As shown in Figure 5, virtually all serum
inhibitory activity based on cAMP production could be found in a
fraction consisting of molecular weights 30,000 to 60,000. Also,
treatment with trypsin decreased the LH receptor stimulating
activity in serum by 96% (cAMP production before treatment
with trypsin 231.9 23.3 pmol/ml; after treatment with trypsin
9.3 1.5 pmol/ml; N = 7), suggesting its proteineous nature.
Analysis of potential inhibition on LH receptor expression
Discussion
The present study demonstrates the presence of circulating
inhibitors of human LH receptors in patients with chronic renal
failure. This factor has a molecular weight between 30,000 and
60,000 Daltons and is believed to he responsible for the impaired
Leydig cell steroidogenesis associated with this condition.
In the testis, Lcydig cells are the only cells containing LH
receptors and capable of androgen biosynthesis. After activation
by specific ligands, LH receptors increase adenylyl cyclase activity
by interacting with membrane-associated G proteins. The result-
ing increase in cAMP ultimately leads to an increase in androgen
synthesis and secretion. Because of the difficulty in obtaining
human testis cells, we used cells expressing recombinant human
LH receptors and measured cAMP production. The assay systems
closest to ours are modifications of rodent interstitial cell LH
bioassays, which are widely used to measure LH bioactivity in
serum and urine. However, the results obtained in LH hioassays
with rodent interstitial cells are not necessarily comparable to an
assay using recombinant human LH receptors, since there are
A
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To ensure that the decreased binding of radiolabeled hCG and
decreased cAMP production were not due to decreased expres-
sion LH receptors we evaluated the LH receptor expression using
immunocytochemistry. Figure 6 shows similar expression of LH
receptors in cells preincubated with either control or uremic
serum, indicating that the results obtained in the hCG binding
0 20 40 60 80 100 experiments were indeed due to non-competitive inhibition of
hCG binding.
Glomerular filtration rate, ml/min/1.73 m2
Fig. 2. Inhibition of camp production in LH receptor-expressing cells by
serum taken from patients with chronic renal failure (cRF,). The cells were
simultaneously coincuhated with a near-saturating concentration (10
nglml) of hCG and patient sera. Inhibition of camp production by the
largest amount of patient serum used (30 ,td) is expressed as a percentage
of the cAMP production by hCG alone. A lower percentage indicates
stronger inhibition (A) at various stages of the disease and (B) in relation
to the glomerular filtration rate. Abbreviations are: transplantation;
Rx, treatment; CAPD, CRF treated with continuous ambulatory perito-
neal dialysis. Data are means of 4 cultures. Symbols are: (•) Cons Rx; (A)
cAPD; (0) after Tx.
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Fig. 3. Displacement of '251-hCG binding to
human LH receptors by hCG or by serum taken
from boys with chronic renal failure (CRF) or
from healthy boys. Cells (2 X I 05/tube)
expressing human LH receptors were incubated
for 18 hours after simultaneously adding 251
hCG with and without varying amounts of hCG
(A) or 30 jsl of patient serum (B). For hCG,
displacement of '251-hCG is shown as a
percentage of the maximal binding with each
amount of unlabeled hormone, whereas for
patient serum, displacement of '251-hCG is
shown as a percentage of the maximal binding
only for the highest amount (30 p1) of patient
serum used. Results (mean SE) are shown for
each group of boys, and the significance of
difference from healthy children is indicated.
(C) The same data in relation to the glomerular
filtration rate; each data point represents one
individual. Abbreviations are: Control, healthy
boys; Tx, transplantation; Rx, treatment;
CAPD, CRF treated with continuous
ambulatory peritoneal dialysis. Symbols are: (•)
Cons Rx; (A) CAPD; (0) after Tx.
clear species differences between rodent and human LH recep-
tors. For instance, recombinant human LH receptors, unlike their
rodent counterparts, are highly species-specific in ligand recogni-
tion, further emphasizing the importance of evaluating ligand-
receptor interactions and signal transduction mechanisms in a
system using human LH receptors [15].
We have previously found that deglycosylated recombinant
hCG hinds to recombinant human LH receptors in a non-
competitive manner, but is incapable of stimulating cAMP pro-
duction, resulting in antagonism of LH action [22]. In the present
study, we found that serum from boys with chronic renal failure
had a similar effect on recombinant human LH receptors as that
previously reported for deglycosylated hCG. The possibility that
chronic renal failure affects the glycosylation process of pituitary
hormones resulting in antagonism of receptor action by the
naturally occurring receptor agonists remains to be investigated.
In addition to the observed antagonism at the LH receptors,
serum from patients with chronic renal failure has been shown to
decrease growth hormone and prolactin binding in rat liver
membranes [23] and also to decrease the stimulation of SO4
uptake by hypophysectomized rat costal cartilage in vitro [24],
suggesting that growth hormone, prolactin, and insulin-like
growth factor receptors are also down-regulated in chronic renal
failure. Yet another impairment in receptor function and expres-
sion has been reported in low-density lipoprotein receptors in
lymphocytes from uremic patients [251. Although the molecular
mechanisms underlying these changes in plasma membrane-
bound receptor functions are unclear at present, the clinical
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Fig. 4. Competition for '251-hCG binding to human LH receptors by serum from a patient with chronic renalfailure. Cells (2 X 105/tube) expressing human
LH receptors were incubated with increasing concentrations of 1251-hCG in the absence or presence of different amounts of patient serum. Levels of
specifically bound '251-hCG (A) are shown together with the derived Lineweaver-Burk plot (B). Symbols are: (0) no serum; (•) serum 3 p1/tube; (A)
9 p1/tube.
Table 2. Effect of coincubation with patient serum and hCG on the
maximal binding and dissociation constant (Kd) of '251-hCG binding to
recombinant human LH receptors
Co-incubation with
Human LH receptor
Maximal binding Apparent Kd
patient serum pg/tube 10—10 M
0 p1/tube 121.0 3.1 2.3 0.05
1 id/tube 109.1 3.4 2.1 0.04
3 p1/tube 72.6 2.5a 2.2 0.06
9 p1/tube 39.0 2.4k 2.8 0.15
Human LH receptor-expressing cells (2 >< 105/tube) were incubated
with increasing concentrations of '251-hCG in the absence or presence of
varying concentrations of patient serum as indicated. Serum and radiola-
beled hormones were added simultaneously. Values are means SE.
Lineweaver-Burk analysis was used to derive apparent K.d and maximal
binding values. Results of three separate experiments are included.
'P < 0.01, b P < 0.005, significantly different from the group not
coincuhated with patient serum
consequences are evident. Down-regulation of GH and insulin-
like growth factor receptors are probably associated with poor
growth in children [23, 24], and decreased low-density lipoprotein
receptor expression and function likely result in hyperlipoprotcin-
emia [25] in chronic renal failure.
Evidence for hypothalamic-pituitary involvement in the hypo-
gonadism associated with chronic renal failure was recently
obtained in uremic rats, which were found to have decreased rates
of GnRH and LH secretion and decreased frequency of LH, but
not of GnRH secretory pulses [8]. Similar alterations have also
been reported in men with chronic renal failure [11]. The involve-
Molecular weight of fraction, kDa
Fig. 5. Estimation of the molecular size of circulating inhibitor of LH
receptors in patients with CRF. Serum from five patients with CRF were
fractionated using Centricon microeoncdntrators followed by the analysis
of the inhibitory activity on cAMP production. The cells were simulta-
neously coincubated with a near-saturating concentration (10 ng/ml) of
hCG and patient sera. tnhibition of camp production by the largest
amount of patient serum used (30 p1) is expressed as a percentage of the
cAMP production by hCG alone. A lower percentage indicates stronger
inhibition. Numbers under the bars indicate the range in molecular
weights in kDa. Results are individual and mean SE values.
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ment of the hypothalamo-pituitary system can be explained by a
circulating LH receptor inhibitor, since LH receptors are ex-
pressed in the central nervous system [26], and receptor inhibition
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Fig. 6. identification of LH receptor expression
in 293 cells transfected with human LH receptor
cDNA. The cells were preincubated with uremic
serum (A) or control serum (B) followed by
immunocytochemical identification of LH
receptor protein (details are in the Methods
section). Panels A and B show similar receptor
expression. For the negative control, non-
transfected 293 cells were used (C). These cells
were treated as in panel B. Reproduction of
this figure in color was made possible by a
grant from Pharmacia Upjohn Oy, Finland.
may therefore be expected to result in modulation of the GnRH
pulse generator.
Serum samples from boys with chronic renal failure inhibited
receptor binding of '251-hCG, suggesting that the serum inhibitor
may interact with the ligand-binding domain of the human LH
receptor. Further biochemical characterization of the receptor
inhibitor should allow the identification of a novel naturally
occurring antagonist of LH receptors.
The LH receptor-inhibiting factor in CRF appears to be a large
protein with molecular weight between 30,000 and 60,000 Dal-
tons. This molecular weight range excludes the possibility that the
receptor stimulating factor is an intact immunoglobulin molecule.
Furthermore, the molecular weight range excludes the possibility
of any toxic effects on the assay system caused by drugs used for
treatment of CRF.
In conclusion, we have demonstrated that patients with CRF
have a circulating factor capable of interacting with recombinant
human LH receptors by inhibiting cAMP production. This factor
may be involved in the pathogenesis of delayed sexual maturation
in these patients. The recognition of novel receptor inhibitors in
chronic renal failure was made possible by the new recombinant
human LH receptor-based bioassay, which may also provide a
useful tool for the diagnosis of other forms of hypogonadism.
Furthermore, this assay may raise new possibilities for monitoring
the extent of the functional gonadal involvement in the patients.
Characterization and purification of this factor will provide a new
antagonist for human LH receptors.
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